Sulfonyl derivatives
US6747023B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2001 |
| Grant date | Jun 8, 2004 |
| Priority date | — |
| Expiry date | Feb 12, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Described in the present invention are a sulfonyl derivative represented by the following formula (I):Q1—Q2—T1—Q3—SO2—QA  (I)[wherein Q1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent;Q2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C1-6 alkylene group or the like;QA represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; andT1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.